ALRN Aileron Therapeutics Inc.

1.07
-0.08  -7%
Previous Close 1.15
Open 1.15
Price To Book 2.23
Market Cap 28583570
Shares 26,713,617
Volume 130,346
Short Ratio
Av. Daily Volume 193,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted that development to be discontinued - no pivotal trial.
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 1/1b data due 4Q 2019.
ALRN-6924 and Cytarabine (Ara-C)
Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)
Phase 2a preliminary data due at ESMO Sept 27-Oct 1, 2019.
ALRN-6924 and IBRANCE (palbociclib)
Solid tumors
Phase 1 has been initiated.
ALRN-6924 and Paclitaxel
Breast cancer
Phase 1b/2 trial to commence September 2019 with data due 1H 2020.
ALRN-6924
Small Cell Lung Cancer (SCLC)

Latest News

  1. Aileron Therapeutics Reports First Quarter 2019 Financial Results
  2. Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8
  3. Aileron Therapeutics Completes $26M Private Placement
  4. Aileron Therapeutics Announces Pricing of $26M Private Placement
  5. Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
  6. 4 Healthcare Stocks Looking To Start February Off Strong
  7. Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here's Why
  8. Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
  9. Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful?
  10. Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
  11. Aileron Inks Collaboration Deal With Pfizer for Cancer Combo
  12. Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
  13. Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth
  14. Aileron Therapeutics Reports Third Quarter 2018 Financial Results
  15. Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
  16. Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
  17. Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018